Access to medicines challenges in Europe: What is wrong and the way forward Presented by: Rohit Malpani Director of Policy & Analysis, Access Campaign.

Slides:



Advertisements
Similar presentations
A TRADE FRAMEWORK FOR INTELLECTUAL PROPERTY RIGHTS, EQUITY PRICING AND MARKET SEGMENTATION Juan Rovira The World Bank Health, Nutrition and Population.
Advertisements

Differential pricing and access to medicines: issues and options Andrew Creese Essential Drugs and Medicines Policy Health Technology and Pharmaceuticals.
1 WTO and medicines: from Doha to Cancún Germán Velásquez Essential Drugs and Medicines Policy World Health Organization Geneva, October 2003.
Prize for TB low-cost point of care rapid diagnostic test Pierre Chirac Médecins Sans Frontières, Paris, France Campaign for Access to Essential Medicines.
Actions Developing in Countries Accessing the WTO System Vung Tau, February 2006 “US – Brazil Compulsory licensing.
ART: The Basics William Aldis World Health Organization Bangkok, September 14, 2005.
UNITAID Innovative Financing Mechanism  Denis Broun Executive Director.
Pharmaceuticals and Global Health: Successes, Challenges and Outlook 19. July 2013, University of Sussex Thomas B. Cueni, Secretary General Interpharma.
The Medicines Patent Pool advancing innovation, expanding access, promoting public health Charles Clift Chair, Medicines Patent Pool
XIX International AIDS Conference July 2012 Washington DC, USA The Brazilian experience: the campaign for access to lopinavir/ritonavir and efavirenz compulsory.
The Medical Innovation Prize Fund S.2210, 110 th U.S. Congress David Reynolds, DrPH Senior Health Policy Advisor Senator Bernie Sanders
“Using Competition Law to Promote Access to Health Technologies” Access to Innovation: Making Generic Versions of Newer ARVs Affordable 24 July 2014 Melbourne,
Health Professional Students AIDS Advocacy Network Treat the People: Access to Essential AIDS Medications A Primer for Health Professional Students.
Global Markets and International Marketing
 Broad-based health care company that discovers, develops, manufactures, and markets products and services  Abbott's main businesses: ◦ Global pharmaceuticals.
The use of TRIPS flexibilities to protect health in South Africa and the opportunities for pro-public health reform of national legislation Nokhwezi Hoboyi.
IP News 指導老師:李柏靜 學生:黃馨葦 M /3/26.  Citing the high cost of one of the pharmaceutical industry's expensive new cancer drugs, India's patent.
EU-India Free Trade Agreement: What future for patients in developing countries Tido von Schoen-Angerer Médecins Sans Frontières - Access to Essential.
Access to Innovation: Making Generic Versions of Newer Antiretrovirals Affordable Focusing on middle income countries Leena Menghaney, MSF Access Camapign.
Intellectual Property and Access to Affordable Medicines: TRIPS Plus
1 Intellectual Property Rights in Medicines Procurement Patrick Osewe Senior HIV/AIDS Specialist World Bank.
A very short introduction to patents & access to medicines.
Medicines & Related Substances Amendment Bill: Protecting the Nation’s Health “The State must take reasonable legislative and other measures, within its.
How can trade contribute to growth and jobs? The role of EU trade policy Signe Ratso Director Directorate General of Trade European Commission.
The Role of TNCs and AIDS drugs – “Lives before profits”? L.O.s 1.To define the terms: TNC, Generic, “Big Pharma”, ARVs, HAART, Tiered Pricing. 2.To describe.
How can Seychelles in future obtain affordable, good quality medicines for HIV/AIDS, Hepatitis C, cancer and other non-communicable diseases? Medical View.
Part Two The Global Environment and Social and Ethical Responsibilities 5 Global Markets and International Marketing.
Total health ODA commitments, US$ Billions.
PATENTS AND HEALTH. A CASE STUDY OF THE UGANDAN CONTEXT. (PHA3 JULY 7 TH 2012 –CAPE TOWN, SOUTH AFRICA) MS. MARIAM AKIROR LLB (HONS) / DIP. SW / CPC. PROG.
UNITAID The HIV/AIDS Medicines Patent Pool Initiative October 2010.
Pricing and the Pharmaceutical Industry What’s Realistic? What’s Smart? What’s Right?
TRIPS plus FTAs Rohit Malpani Oxfam America. Public health consequences of TRIPS plus FTAs Prospective studies on FTAs with TRIPS plus provisions –US.
1 MIAG 2 Response to Industry -Emerging markets Eva M A Ombaka.
Competitiveness of the European-based Pharmaceutical Industry Prospective of a New Member State Imre Hollo Deputy Secretary of State, MOH Hungary.
Getting the best treatment to the most people possible Enabling policies: threats & opportunities MSF Access Campaign.
Paula Munderi Department of Essential Drugs and Medicines Policy World Health Organization Access to essential medicines for HIV/AIDS - update on WHO activities.
Title text here Consumer Perspective on Containing Drug Costs Leigh Purvis, Director, Health Services Research.
UNCTAD/CD-TFT 1 Exclusive Rights and Public Access – Flexibilities in International Agreements and Development Objectives The Public Health Example 21.
Intellectual Property Rights and Pharmaceuticals (Case study- Novartis’s claim in India) Background note prepared for PHM Vic Internet Workshop.
Pricing and the Pharmaceutical Industry What’s Realistic? What’s Smart? What’s Right?
Treating MDR-TB A Challenge Throughout ECA Public Health Practice II.
AMC Governance and Institutional Support. Objectives Build on existing capacity Ensure appropriate independence and credibility through transparency,
TRIPS TRIPS is the Agreement on Trade Related Aspects of Intellectual Property Rights Framed within the WTO, by “consensus” Regulates intellectual property.
Affordability of HIV/AIDS treatment in developing countries: an analysis of ARV drug price determinants Luis Sagaon Teyssier; Yves Arrighi; Boniface Dongmo.
PATENT POOL & its CONCERNS PATENT POOL & its CONCERNS Manmohan A Amonkar 20 July 2010.
Managing Procurement and Logistics of HIV/AIDS Drugs and Related Supplies By Yvonne Nkrumah Legal Counsel, Ghana Food and Drugs Board.
World Health Organization "3 by 5" Target Treat 3 million by 2005.
Donors, prize funds and patent pools. KEI & UNU- MERIT Maastricht Workshop on Medical Innovation Prizes January 28th-29th 2008 Michelle Childs, Head of.
Ellen ‘t Hoen Médecins sans Frontières
Tensions between Brazil and the United States
Access to Medicines Making Innovation work for the poor Corinna Heineke Diversity in Innovation European Patent Conference, Brussels, 15/16 May 2007.
Part Two Using Technology for Customer Relationships in a Global Environment Global Markets and International Marketing 5 5.
Uniting Forces for Access to Hepatitis C Treatment Global Epidemiology Global Epidemiology & Treatment Access Issues & Treatment Access Issues Tracy Swan.
WHO Medicines Strategy Progress: Priorities: Dr Guitelle Baghdadi Essential Drugs and Medicines Policy World Health Organization November.
Washington D.C., USA, July 2012www.aids2012.org An advocacy tool: Untangling the Web of Antiretroviral Price Reductions Arax Bozadjian HIV Focused.
Strategies to increase access to high priced medicines and vaccines: lessons, new challenges and opportunities Judit Rius Sanjuan U.S. Manager & Legal.
Introduction: Intellectual Property Rights and its impact on access to medicines Anand Grover United Nations Special Rapporteur on Health East Africa Consultation,
IMPROVING ACCESS AND INNOVATION IN HIV THROUGH VOLUNTARY LICENSING: THE EXPERIENCE OF THE MEDICINES PATENT POOL ICASA – Harare, Zimbabwe Session on Innovation.
NAFTA, CAFTA and Access to Medicines and Food Security in Latin America International Aids Conference Session “Globalization and FTAs: their impact, access.
ANTI COUNTERFEIT FROM COMMUNITY PERSPECTIVE -Estimates indicates 30% of drugs in Kenyan market are fake. -40 billion lost every year due to counterfeit.
Moving towards a Patent Pool? XVII International AIDS Conference Satellite Forum, MSF, KEI, OXFAM (Mexico, 5 August 2008) Jorge Bermudez Executive-Secretary,
iHEA 9th World Congress Sydney, July 8, 2013
Intellectual Property and Access to Affordable Medicines: TRIPS Plus
How Advocacy can Influence Pricing & Policy
Intellectual Property Protection and Access to Medicines
Making medicines, diagnostics and other commodities more affordable
Carnegie Institution of Washington
Charting a new course for HIV and health in Africa:
Treat the world: Working united across diseases for quality and affordable treatment for all – AIDS 2018 TRIPS Flexibilities 0.2 Across Diseases Ellen.
The problem of high prices
Presentation transcript:

Access to medicines challenges in Europe: What is wrong and the way forward Presented by: Rohit Malpani Director of Policy & Analysis, Access Campaign MSF Access Campaign

Médecins Sans Frontières (MSF), founded in 1971, is an international, independent, medical humanitarian organization that delivers emergency aid in 70 countries. MSF in Greece has had operations in Greece since 1991 and currently works with migrants at detention facilities in the north and has established a project in the Athens city centre that focus in particular on vulnerable people. MSF’s Access Campaign works to promote increased access to life-saving medicines, vaccines and promote increased R&D of new medical tools that meet patient needs. About Médecins Sans Frontières (MSF)

Generic Competition and HIV Treatment Scale-Up $10,400 $2700

Impact of patent monopolies

Extreme disparity between cost of manufacturing and product price Sofosbuvir – new Hepatitis C drug recently approved by the European Medicines Agency and Food and Drug Administration In combination with other drugs, successfully treat Hepatitis C in weeks depending on genotype. Cost of manufacturing of Sofosbuvir for 12 week course: Between 50 and 100 Euros Estimated price in the United States and EU for 12 week course: Approximately 60,000 Euros MSF Access Campaign

Tiered pricing: best strategy? Some major weaknesses: a)Price: reductions not reliable, not lowest, not sufficient b)Arbitrary: categories, products and price premiums c)Lack of transparency d)Whose responsibility: firms or governments? Source: Moon S, Jambert E, Childs M, von Schoen-Angerer T “A ‘win-win’ solution?: A critical analysis of tiered pricing to improve access to medicines in developing countries.” Globalization and Health 7:39. doi: / Available:

MSF Access Campaign Source: MSF Untangling the Web of Antiretroviral Price Reductions, 15 th Edition, July 2012 The most affordable second-line regimen is still twice as expensive as the WHO recommended first-line regimen The price of a third-line regimen is more than 14 times higher than the recommended first-line Tiered pricing for ARVs: Treatment time bomb Source: MSF Untangling the Web of antiretroviral Price Reductions, 15 th Edition, July 2012

GAVI $7 PAHO ~$15 South Africa $20 Macedonia $89 Sources: PAHO Revolving Fund price list, UNICEF Supply Division GAVI Price List, South Africa DoH personal correspondence (7Nov2012), SAGE Presentation (8Nov2012) MSF feedback on price: vaccines too expensive (PCV price per dose comparison) GAVI Alliance Advanced Market Commitment (AMC) PAHO Revolving Fund - $14.24 (PCV10), $16.34 (PCV13) Republic of South Africa Macedonia Greece?

MSF Access Campaign Source: MSF Untangling the Web of Antiretroviral Price Reductions, 15 th Edition, July 2012 Public health safeguards to improve access Range of public health safeguards protected under World Trade Organization rules, including compulsory licensing and tighter patentability rules. India granted its first compulsory license to allow generic production and sale of Sorafenib (cancer medicine). Ensure patents are only granted for true innovations, not legal innovations. Avoid ever-greening.

MSF Access Campaign Source: MSF Untangling the Web of Antiretroviral Price Reductions, 15 th Edition, July 2012 Public health safeguards to improve access? Bedaquiline (TB): 30,000 Euros in high-income countries, 3,000 Euros in middle income countries. Simeprivir (Hepatitis C): 48,000 Euros in high-income countries. Herceptin (breast cancer): Greek patients must pay a Euros copayment for branded versions of the medicine. November 27, 2013: Generic equivalent of Herceptin approved in India.

MSF Access Campaign Source: MSF Untangling the Web of Antiretroviral Price Reductions, 15 th Edition, July 2012 European Commission: Where is the commitment to access? Pressure imposed on developing countries that employ compulsory licensing and other safeguards to ensure affordable treatment. Supports tiered pricing as the solution to access. Negotiating free trade agreements that would limit ability of EU Member States to use public health safeguards. European Union Competition Commission: Anti- competitive intellectual property strategies cost EU consumers 2 billion Euros between 2000 and 2007.

MSF Access Campaign Source: MSF Untangling the Web of Antiretroviral Price Reductions, 15 th Edition, July 2012 The way forward Re-thinking the ‘bottom billion’. Full use of safeguards available under global trade rules to manage medicine prices. Don’t tie the hands of EU Member States to improve access to medicines. EU taxpayers should not pay twice for medicines.